Gilead Calls Forty Seven Buyout Complementary To Kite, Other IO Efforts

 
• By Joseph Haas
  
Business PEOPEL Assembling JIGSAW Puzzle
Forty Seven's anti-CD47 candidates add new potential to Gilead's IO pipeline
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business